Skip to content
Chiesi
-
Chiesi strengthens rare disease portfolio with US$1.9B acquisition of KalVista
Under the terms of the agreement, Chiesi will purchase KalVista for US$27 per share, representing a 36% premium over the company’s closing stock price on April 28.